Endobronchial Ultrasound-guided Transbronchial Needle Biopsy for Diagnosis of Mediastinal Lymphadenopathy in Patients with Extrathoracic Malignancy.
10.3346/jkms.2011.26.2.274
- Author:
Jinkyeong PARK
1
;
Se Jin JANG
;
Young Soo PARK
;
Yeon Mok OH
;
Tae Sun SHIM
;
Woo Sung KIM
;
Chang Min CHOI
Author Information
1. Department of Pulmonary and Critical Care Medicine, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, Korea. ccm@amc.seoul.kr
- Publication Type:Original Article
- Keywords:
EBUS;
Extrathoracic Malignancy;
Mediastinal Adenopathy;
Metastatic Cancer of Unknown Primary Site;
MUO
- MeSH:
Adult;
Aged;
Aged, 80 and over;
Biopsy, Needle/*methods;
Endosonography/*methods;
Humans;
Lymph Nodes/pathology/ultrasonography;
*Lymphatic Diseases/diagnosis/surgery/ultrasonography;
*Lymphatic Metastasis/diagnosis/pathology;
Male;
*Mediastinal Neoplasms/diagnosis/surgery/ultrasonography;
Middle Aged;
Neoplasms/*pathology;
Retrospective Studies;
Young Adult
- From:Journal of Korean Medical Science
2011;26(2):274-278
- CountryRepublic of Korea
- Language:English
-
Abstract:
Mediastinal lymphadenopathy associated with extrathoracic malignancy or a metastasis of unknown origin (MUO) requires pathological verification. Surgical exploration or endoscopic ultrasound-guided fine needle aspiration is limited to application. We investigated the effectiveness of endobronchial ultrasound-guided transbronchial needle biopsy (EBUS-TBNA) for evaluating mediastinal lymphadenopathy in patients with an extrathoracic malignancy. We retrospectively analyzed data from 59 patients who underwent EBUS-TBNA with a core biopsy because of a suspected mediastinal metastasis between September 2008 and August 2010. All patients had previously been diagnosed with an extrathoracic malignancy (n = 39, 66.1%) or a suspected MUO without a thoracic lesion (n = 20, 33.9%). A total of 88 lymph nodes was analyzed. EBUS-TBNA findings indicated malignancies in 34 patients (57.6%). The EBUS-TBNA sensitivity and specificity for the detection of mediastinal malignancy in patients with a previous extrathoracic malignancy were 96.3% and 100%, respectively. For MUO patients without a thoracic lesion, the sensitivity and specificity were 61.5% and 100%, respectively. The overall sensitivity and specificity were 81.0% and 100%, respectively (P = 0.053). EBUS-TBNA is a safe and effective modality for evaluating mediastinal lymphadenopathy in patients with a previous extrathoracic malignancy or a MUO without a thoracic lesion. The application of this diagnostic tool is likely to have significant clinical implications.
